Zobrazeno 1 - 10
of 12
pro vyhledávání: '"Gabriel Malouf"'
Autor:
Xiaoping Su, Gabriel Malouf
Publikováno v:
HemaSphere, Vol 7, p e656824a (2023)
Externí odkaz:
https://doaj.org/article/9b46340be2ae419fbeb1b3f9ef384ed3
Autor:
Yann-Alexandre Vano, Sylvain Ladoire, Réza Elaidi, Slimane Dermeche, Jean-Christophe Eymard, Sabrina Falkowski, Marine Gross-Goupil, Gabriel Malouf, Bérangère Narciso, Christophe Sajous, Sophie Tartas, Eric Voog, Alain Ravaud
Publikováno v:
Cancers, Vol 13, Iss 21, p 5548 (2021)
The development of antiangiogenic treatments, followed by immune checkpoint inhibitors (ICI), has significantly changed the management of metastatic clear cell renal cell cancer. Several phase III trials show the superiority of combination therapy, d
Externí odkaz:
https://doaj.org/article/becd57d4d59b43458af2ace5bd8612ce
Autor:
Victor Gaillard, Albane Lhuillier, Cécile Bigot, Laure Pierard, Philippe Trensz, Mickael Burgy, Caroline Schuster, Gabriel Malouf, Aurélie Fritsch, Hervé Lang, Thibault Tricard, Delphine Borchiellini, Lionnel Geoffrois, Philippe Barthelemy
Publikováno v:
Supportive Care in Cancer. 30:6583-6591
Tyrosine kinase inhibitors (TKIs) remain a cornerstone of metastatic kidney cancer (mRCC). Adverse events (AEs) may lead to dose downregulation, and optimal management of AEs is needed to maintain an efficient dose intensity (DI). The aim of our stud
Autor:
Vicky Katopodi, Irwin Davidson, Ewout Demesmaeker, Gabrielle MENGUS, Eleonora Leucci, Giovanni Gambi, Tiziana Bonaldi, Alessandro Cuomo, Guillaume Davidson, Gabriel Malouf
Tumor heterogeneity is a key feature of melanomas that hinders development of effective treatments. Aiming to overcome this, we identified LINC00518 (LENOX; lincRNA-enhancer of oxidative phosphorylation) as a melanoma-specific lncRNA expressed in all
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9ffd457f0a69b04e7d140d73867fdaeb
https://lirias.kuleuven.be/handle/20.500.12942/705860
https://lirias.kuleuven.be/handle/20.500.12942/705860
Autor:
Gabriel Malouf, Xiaofan Lu, Yann Vano, Alexandra Helleux, Xiaoping Su, Véronique Lindner, Guillaume Davidson, Roger Mouawad, Jean-Philippe Spano, Morgan Rouprêt, Reza Elaidi, Eva Compérat, Virginie Verkarre, Chengming Sun, Christine Chevreau, Mostefa Bennamoun, Hervé Lang, Thibault Tricard, Wenxuan Cheng, Li Xu, Irwin Davidson, Fangrong Yan, Wolf FRIDMAN, Catherine Sautès-Fridman, Stéphane Oudard
Immune checkpoint inhibitors have revolutionized the treatment of patients with clear-cell renal carcinomas. Although, analyses of transcriptome, genetic alterations, and the tumor microenvironment have shed light into mechanisms of response and resi
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::9ba383af6abe0a5fc4581f18492e2fe8
https://doi.org/10.21203/rs.3.rs-1673570/v1
https://doi.org/10.21203/rs.3.rs-1673570/v1
Autor:
Bujamin Vokshi, Guillaume Davidson, Alexandra Helleux, Marc Rippinger, Alexandre Haller, Justine Gantzer, Philippe Baltzinger, Jonathan Thouvenin, Rachida Bouarich-Bourimi, Valentina Manriquez, Sakina Zaidi, Pavlos Msaouel, Xiaoping Su, Hervé Lang, Thibault Tricard, Véronique Lindner, Didier Surdez, Jean-Emmanuel Kurtz, Franck BOURDEAUT, Nizar Tannir, Irwin Davidson, Gabriel Malouf
Renal medullary carcinoma (RMC) is an aggressive tumour driven by bi-allelic loss of SMARCB1 and tightly associated with sickle cell trait. However, the cell-of-origin and oncogenic mechanism remain poorly understood. Using single-cell sequencing of
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::bf5a58b6653320a21103a472808302ca
https://doi.org/10.21203/rs.3.rs-1178801/v1
https://doi.org/10.21203/rs.3.rs-1178801/v1
Autor:
Omar Alhalabi, Jonathan Thouvenin, Sylvie Negrier, Yann-Alexandre Vano, Luca Campedel, Elshad Hasanov, Ziad Bakouny, Andrew Warren Hahn, Mehmet Asim Bilen, Toni K. Choueiri, Srinivas Raghavan Viswanathan, Kanishka Sircar, Laurence Albiges, Gabriel Malouf, Nizar M. Tannir
Publikováno v:
Journal of Clinical Oncology. 40:343-343
343 Background: IO combinations are standard of care for first-line therapy of clear-cell RCC; however, non-clear cell histologies including tRCC were not included in the registrational trials. We previously reported a modest efficacy (objective resp
Autor:
Kasmintan Schrader, Paul Cohen, Johan Bulten, Matthew Richardson, Paolo Peterlongo, Katja Gaarenstroom, Edenir Palmero, Nuria Romero-Laorden, Barbara Rivera, Miguel De la Hoya, Dimcho Bachvarov, Cristiano De Pádua Souza, Lorena Magraner-Pardo, Joanne Ngeow, Marco Montagna, Gabriel Malouf
Publikováno v:
Current Oncology. 25:224-262
The comprehensive assessment of inherited mutations in cancer susceptibility genes helps to optimize clinical decision-making [...]
Autor:
Luca, Campedel, Myriam, Kossaï, Paul, Blanc-Durand, Morgan, Rouprêt, Thomas, Seisen, Eva, Compérat, Jean-Philippe, Spano, Gabriel, Malouf
Publikováno v:
Bulletin du cancer. 104(9)
Neuroendocrine prostate cancer is a rare malignancy with a an adverse prognostic. Histologically, It can be pure (small cells or large cells neuroendocrine carcinoma) or mixed with a adenocarcinoma component. Rarely diagnosed de novo, neuroendocrine
Autor:
Bernard, Caillou, Gabriel, Malouf
Publikováno v:
Annales de pathologie.